319 IBD Flashcards
Two major types of IBD
Ulcerative colitis (UC) and Crohn’s disease (CD)
Peak incidence of IBD
second to fourth decade of life
Defined as IBD that occurs in children age less than 6 years
very early onset IBD (VEOIBD)
Defined as IBD that occurs in children age less than 2 years
Infantile IBD
Commonly affected part by VEOIBD and infantile IBD
colon, resistant to standard medication and have a strong family history of IBD
True or false. Infectious gastroenteritis with pathogens such as salmonella, shigella, campylobacter, clostridium increases IBD risk
true.
True or false. Protective effect of Vitamin D has been reported on risk of CD
true.
major host components that function together as an integrated supraorganism
microbiota, Intestinal epithelial cells, and immune cells
Current pathogenesis of IBD
inappropriate immune response to the endogenous (autochthonous) commensal microbiota within the intestines, with or without some component of autoimmunity
Genetic risk factors that are shared with IBD
rheumatoid arthritis, psoriasis, ankylosing spondylitis, type 1 diabetes mellitus, asthma, and systemic lupus erythematosus
True or false. Endogenous commensal microbiota within the intestines plays a central role in the pathogenesis of IBD
true.
True or false. The microbiota is considered as a critical and sustaining component of the human organism
true.
3 major CD4 T helper cells that promote inflammation
TH1 cells, TH2 and TH17
Mucosal disease that usually involves the rectum and extends proximally to involve all or part of the colon
Ulcerative colitis
associated with backwash ileitis
Ulcerative colitis
asssociated with skip lesions
Crohns disease
mucosa is erythematous and has a fine granular surface that resemble sandpaper
Ulcerative colitis
presence of pseudopolyps as a result of epithelial regeneration
both UC and CD
in fulminant disease can develop toxic colitis or megacolon where the bowel wall thins and mucosa is severely ulcerated and leads to perforation
ulcerative colitis
True or false. In ulcerative colitis, the disease process is limited to the mucosa and superficial submucosa with deeper layers unaffected except in fulminant disease
true.
True or false. Pancreatitis is a rare extraintestinal manifestation of IBD
True.
agents effective in inducing and maintaing remission in patietn with UC
5 ASA agents
effective treatment for mild to moderate UC is occasionally used in Crohns colitis
sulfasalazine
contains azo bond mesalamine; it is effective in the colon
balsalazide
enteric coated form of mesalamine with the 5 ASA being released at pH more than 7
Delzicol and Asacol HD
once a day formulation of mesalamine designed to release mesalamine in colon
Lialda
encapsulated mesalamine granules that delivers mesalamine to the terminal ileum and colon
Apriso
once a day formation of mesalamine
Lialda and Apriso
another mesalamine formation that uses ethylcellulose coating to allow water absorption into small beads containing the mesalamine
Pentasa
started in patient with UC unresponsive to 5- ASA
prednisone
how are parenteral glucocorticoids given
Hydrocortisone 300 mg/d or methyprednisolone 40-60 mg/d
True or false. Antibiotics have no role in the treatment of active or quiescent UC
True.
True or false. Pouchitis however responds to treatment with metronidazole and ciprofloxacin
True.
what is effective in active inflammatory, fistulizing and perianal CD and what is the dosage
metronidazole at 15-20 mg/kg per day divided in 3 doses
beneficial for inflammatory perianal and fistulizing CD but has been associated with tendinitis and tendon rupture
ciprofloxacin
purine analogues used as immunosuppresant
azathrioprine and 6 mercaptopurine
side effect of azathiorprine and 6 mercaptopurine
pancreatitis
used most often concomitantly with biologic therapy to decrease antibody formation and improve disease response; it inhibits dihydrofolate reductase
methotrexate
rare complication of methotrexate
hypersensitivity pneumonitis
lipophilic peptide with inihibitory efefcts on both the cellular and humoral immune systems and given to severe UC that is refractory to IV glucocorticoids
cyclosporing (CSA)
macrolide antibiotic with immunodulatory properties similar to CSA and effective in adults with extensive involvement of the small bowel
tacrolimus
initial therapy for patients with moderate to severe CD and UC
biologic therapies such as anti TNF therapies
first biologic therapy approved for moderate to severely active CD and UC; chimerici IgG1 antibody against TNF alpha
infliximab
recombinant human monoclonal IgG1 antibody containing only human peptides sequences; binds TNF and neutralizes its function
adalimumab
pegylated form of anti TNF fab portion of antibody
certolizumab
another fully human IgG1 antibody against anti TNF alpha
golimumab
side effect of anti TNF therapies leading to increased risk of infusion reactions and a decreased response to treatment
development of antibodies
common practice to prevent antibody formation in anti TNF therapies
add an immunomodulator such as azathiorprine, 6 mercaptopurine or MTX